Privium Fund Management B.V. - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 145 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2024. The put-call ratio across all filers is 2.99 and the average weighting 0.2%.

Quarter-by-quarter ownership
Privium Fund Management B.V. ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$823,200
-16.7%
40,000
+29.0%
0.21%
-20.5%
Q1 2024$987,660
+38.0%
31,000
-8.0%
0.26%
+32.7%
Q4 2023$715,700
+66.9%
33,6800.0%0.20%
+55.5%
Q3 2023$428,74633,6800.13%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q2 2024
NameSharesValueWeighting ↓
VR Adviser, LLC 4,400,000$92,356,0005.88%
Deep Track Capital, LP 4,061,401$85,248,8072.54%
BVF INC/IL 3,922,413$82,331,4492.31%
Decheng Capital LLC 347,835$7,301,0572.24%
Novo Holdings A/S 1,400,000$29,386,0001.71%
Eagle Health Investments LP 462,911$9,716,5021.70%
Opaleye Management Inc. 345,750$7,257,2931.66%
RA Capital Management 5,098,211$107,011,4491.42%
Redmile Group, LLC 1,073,435$22,531,4011.36%
Casdin Capital, LLC 800,000$16,792,0001.29%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders